scholarly journals Subcutaneous Immunotherapy With High-Dose Cat and Dog Extracts: A Real-life Study

2020 ◽  
Vol 30 (3) ◽  
pp. 169-174 ◽  
Author(s):  
SA Uriarte ◽  
J Sastre
Keyword(s):  
Real Life ◽  
Subcutaneous Immunotherapy ◽  
High Dose ◽  
Life Study ◽  
Real Life Study

High adherence to subcutaneous immunotherapy in a real-life study from a large tertiary medical center

2017 ◽  
Vol 38 (6) ◽  
pp. 78-84 ◽  
Author(s):  
Aslı Gelincik ◽  
Semra Demir ◽  
Müge Olgaç ◽  
Halim İşsever ◽  
Bayerma Khishigsuren ◽  
...  
Keyword(s):  
Medical Center ◽  
Real Life ◽  
Subcutaneous Immunotherapy ◽  
Life Study ◽  
High Adherence ◽  
Real Life Study

scholarly journals Real-life effect of a microcrystalline tyrosine adjuvanted mite immunotherapy in patients with allergic rhinitis

Immunotherapy ◽  
2020 ◽  
Vol 12 (1) ◽  
pp. 53-62 ◽  
Author(s):  
Albert Roger ◽  
Alfons Malet ◽  
Victoria Moreno ◽  
Antonio Parra ◽  
Diego Gutiérrez ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Treatment Initiation ◽  
Real Life ◽  
Subcutaneous Immunotherapy ◽  
Serious Adverse Events ◽  
End Points ◽  
Life Study ◽  
Real Life Setting ◽  
Medication Score ◽  
Real Life Study

Aim: Evaluate the effectiveness and safety of immunotherapy with Acarovac Plus® in a 1-year prospective multicentered real-life study. Methods: A total of 118 adults with allergic rhinitis sensitized to Dermatophagoides received subcutaneous immunotherapy with Acarovac Plus. Treatment outcomes were evaluated at baseline, 6 months and 1 year after treatment initiation. Primary end point was the evolution of the combined symptom and medication score. Secondary end points included other effectiveness outcomes and measurement of product tolerability. Results: Acarovac Plus induced significant improvements in primary and secondary end points after 6 months compared with baseline. These differences persisted after 1 year of treatment (p < 0.001; baseline vs 1 year): combined symptom and medication score (1.60 vs 0.79). No serious adverse events were recorded. Conclusion: Acarovac Plus for 1 year was effective and well tolerated in a real-life setting.

Quality of life in allergic rhinitis and impact of high-dose sublingual immunotherapy: a real-life study

2006 ◽  
Vol 6 (3) ◽  
pp. 71-73 ◽  
Author(s):  
R. Ariano ◽  
S. Amoroso ◽  
C. Astarita ◽  
M. Bassi ◽  
P. Bonadonna ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Allergic Rhinitis ◽  
Sublingual Immunotherapy ◽  
Real Life ◽  
High Dose ◽  
Life Study ◽  
Real Life Study

Risk factors and strategies in nonadherence with subcutaneous immunotherapy: a real-life study

2018 ◽  
Vol 8 (11) ◽  
pp. 1267-1273 ◽  
Author(s):  
Yongshi Yang ◽  
Yin Wang ◽  
Lin Yang ◽  
Jingru Wang ◽  
Nan Huang ◽  
...  
Keyword(s):  
Risk Factors ◽  
Real Life ◽  
Subcutaneous Immunotherapy ◽  
Life Study ◽  
Real Life Study

Baseline data of the DEVIDE-study: DEnosumab vs Intravenous Ibandronate: a 2-year retrospective head to head real life study

2014 ◽  
Author(s):  
Karin Amrein ◽  
Christian Muschitz ◽  
Doris Wagner ◽  
Thomas R Pieber ◽  
Heinrich Resch ◽  
...  
Keyword(s):  
Real Life ◽  
Baseline Data ◽  
Life Study ◽  
Real Life Study

Pegvisomant: daily versus non daily administration a single centre real life study

2019 ◽  
Author(s):  
Francesca Dassie ◽  
Marco Rosson ◽  
Matteo Parolin ◽  
Lucia Russo ◽  
Sara Mazzocut ◽  
...  
Keyword(s):  
Real Life ◽  
Daily Administration ◽  
Single Centre ◽  
Life Study ◽  
Real Life Study
Sign in / Sign up

Export Citation Format

Share Document